Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients

Medical Oncology

Volumn 28, Issue 4, 2011, Pages 1425-1429

  Dong, Xiaorong ^a   Huang, Jing ^a   Cao, Rubo ^a   Liu, Li ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antiemetic drugs; Chemotherapy; Non small cell lung carcinoma; Palonosetron

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; GEMCITABINE; ONDANSETRON; PACLITAXEL; PALONOSETRON; PEMETREXED;

ACUTE DISEASE; ADULT; AGED; ANXIETY; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; ISOQUINOLINES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; ONDANSETRON; QUINUCLIDINES; VOMITING;

EID: 84655165053     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9608-y     Document Type: Article

References (15)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108
2. RM Navari LH Einhorn PJ Loehrer Sr 2007 A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study Support Care Cancer 15 1285 1291
3. SM Grunberg RR Deuson P Mavros 2004 Incidence of chemotherapy-induced nausea and emesis after modern antiemetics Cancer 100 2261 2268
4. B Bloechl-Daum RR Deuson P Mavros M Hansen J Herrstedt 2006 Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment J Clin Oncol 24 4472 4478
5. PJ Hesketh 2000 Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting Cancer Invest 18 163 173
6. M Kris R Gralla R Clark 1985 Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin J Clin Oncol 3 1379 1384
7. SM Walton 2000 Advances in use of the 5-HT3 receptor antagonists Exp Opin Pharmacother 1 207 223
8. V Gebbia G Cannata A Testa 1994 Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting Cancer 74 1945 1952
9. EA Perez P Hesketh J Sandbach 1998 Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study J Clin Oncol 16 754 760
10. MG Kris PJ Hesketh MR Somerfield 2006 American Society of Clinical Oncology guideline for antiemetics in oncology: up date 2006 J Clin Oncol 24 2932 2947
11. R Gralla S Lichinitser S Van Der Vegt 2003 Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann Oncol 14 1570 1577
12. P Eisenberg J Figueroa-Vadillo R Zamora 2003 Improved prevention of moderately emetogenic chemotherapy induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist Results of a phase III single-dose trial versus dolasetron Cancer 98 11 2473 2482
13. M Aapro S Grunberg G Manikhas 2004 A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Ann Oncol 17 1441 1449
14. National Cancer Institute-Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 2006 [August9].
15. LH Einhorn B Rapoport J Koeller 2005 Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement Support Care Cancer 13 112 116